Home・Akcijų sąrašas・Geron Corp

Geron Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

1.61 20.15

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.34

Max

1.6099999999999999

Pagrindiniai rodikliai
By Trading Economics
Pajamos	25M -3.6M
Pardavimai	3.8M 52M
Pelnas, tenkantis vienai akcijai	-0.005
Pelno marža	-7.026
Darbuotojai	258
EBITDA	27M 3.8M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+198.51% upside

Dividendai
By Acuity
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-185M 821M
Ankstesnė atidarymo kaina	-18.54
Ankstesnė uždarymo kaina	1.61

Naujienos nuotaikos

By Acuity

20%

80%

55 / 340 reitingas Healthcare

Geron Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-04 23:36; UTC

Geron Corp shares are lower in after-market trading, nearing the bottom of their one-month range and below the 20-day moving average.

2026-08-03 23:06; UTC

Geron Corp shares are lower in after-market hours, continuing a steady decline since Monday's close and remaining below the 20-day moving average.

2026-07-31 20:02; UTC

Geron Corp shares are lower as the Biotechnology sub-sector declines. The stock pulled back from an earlier session high, finishing below its 20-day moving average.

2026-07-30 20:56; UTC

Geron Corp shares are higher in after-market hours, influenced by positive corporate earnings amid broader market uncertainty following the Federal Reserve's interest rate decision.

2026-07-29 19:32; UTC

Macro Event

Geron Corp shares are lower as market volatility rises following the Federal Reserve's interest rate decision amid ongoing economic growth and inflation concerns.

2026-07-28 18:51; UTC

Shares of Geron Corp are lower today amid broader market volatility and uncertainty regarding Federal Reserve decisions. The stock declined since Monday's close.

2026-07-27 23:16; UTC

Geron Corp shares are lower in after-market trading, despite earlier gains, with no specific company news driving the decline.

2026-07-24 19:46; UTC

Geron Corp shares are lower in Friday's session amid broader market volatility and uncertainty from fluctuating oil prices and new U.S. tariffs.

2026-07-23 10:11; UTC

Shares of Geron Corp are higher in pre-market hours, trading above their 20-day moving average. No specific company news was identified.

2026-07-22 18:51; UTC

Geron Corp shares are lower today amid broader market trends, as crude oil prices surge due to geopolitical tensions.

2026-07-21 23:41; UTC

Geron Corp shares are lower in after-market trading, declining to their lowest point since Tuesday's close. No specific news was identified to explain the drop.

2026-07-20 23:56; UTC

Geron Corp shares are lower in after-market hours, continuing a decline since Monday's close amid broader market uncertainties and a drop in the leading economic index.

Akcijų palyginimas

Kainos pokytis

Geron Corp Prognozė

Kainos tikslas

By TipRanks

198.51% į viršų

12 mėnesių prognozė

Vidutinis 4 USD 198.51%

Aukščiausias 5 USD

Žemiausias 3 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Geron Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Geron Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

55 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.